SI0901487T1 - 2,3,6 trisubstituted-4(3h)-quinazolinones - Google Patents

2,3,6 trisubstituted-4(3h)-quinazolinones

Info

Publication number
SI0901487T1
SI0901487T1 SI9730555T SI9730555T SI0901487T1 SI 0901487 T1 SI0901487 T1 SI 0901487T1 SI 9730555 T SI9730555 T SI 9730555T SI 9730555 T SI9730555 T SI 9730555T SI 0901487 T1 SI0901487 T1 SI 0901487T1
Authority
SI
Slovenia
Prior art keywords
quinazolinones
trisubstituted
Prior art date
Application number
SI9730555T
Other languages
English (en)
Slovenian (sl)
Inventor
Mark Leonard Elliott
Willard Mckowan Welch Jr.
L. Chenard Bertrand
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI0901487T1 publication Critical patent/SI0901487T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SI9730555T 1996-05-15 1997-02-17 2,3,6 trisubstituted-4(3h)-quinazolinones SI0901487T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15
EP97901749A EP0901487B9 (en) 1996-05-15 1997-02-17 2,3,6 trisubstituted-4(3h)-quinazolinones
PCT/IB1997/000134 WO1997043276A1 (en) 1996-05-15 1997-02-17 Novel 2,3 disubstituted-4(3h)-quinazolinones

Publications (1)

Publication Number Publication Date
SI0901487T1 true SI0901487T1 (en) 2003-10-31

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730555T SI0901487T1 (en) 1996-05-15 1997-02-17 2,3,6 trisubstituted-4(3h)-quinazolinones

Country Status (39)

Country Link
US (1) US6303615B1 (no)
EP (1) EP0901487B9 (no)
JP (1) JP3241388B2 (no)
KR (1) KR100375155B1 (no)
CN (2) CN1103772C (no)
AP (1) AP1148A (no)
AR (1) AR007118A1 (no)
AT (1) ATE242232T1 (no)
AU (1) AU730503B2 (no)
BG (1) BG102999A (no)
BR (1) BR9709085A (no)
CA (1) CA2252907C (no)
CZ (1) CZ295565B6 (no)
DE (1) DE69722613T2 (no)
DK (1) DK0901487T3 (no)
DZ (1) DZ2237A1 (no)
EA (1) EA002905B1 (no)
ES (1) ES2198546T3 (no)
GT (1) GT199700049A (no)
HK (1) HK1019607A1 (no)
HN (1) HN1997000052A (no)
HR (1) HRP970261B1 (no)
HU (1) HUP9902148A3 (no)
ID (1) ID17149A (no)
IL (1) IL126589A (no)
IS (1) IS4881A (no)
MA (1) MA26430A1 (no)
NO (1) NO985293L (no)
OA (1) OA10918A (no)
PL (1) PL330042A1 (no)
PT (1) PT901487E (no)
SI (1) SI0901487T1 (no)
SK (1) SK284108B6 (no)
TN (1) TNSN97087A1 (no)
TR (1) TR199802296T2 (no)
TW (1) TW539675B (no)
WO (1) WO1997043276A1 (no)
YU (1) YU19197A (no)
ZA (1) ZA974156B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ336627A (en) * 1997-02-28 2000-12-22 Pfizer Prod Inc Atropisomers of 3-heteroaryl-4(3)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions
IL130900A0 (en) * 1997-02-28 2001-01-28 Pfizer Prod Inc Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
CA2362385C (en) 1999-02-15 2009-08-11 Eisai Co., Ltd. Heterodiazinon compound
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP2006501201A (ja) * 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
US20100152209A1 (en) * 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN104211684A (zh) * 2007-09-26 2014-12-17 细胞基因公司 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
MY153733A (en) 2008-01-30 2015-03-13 Shin Poong Pharmaceutical Co Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
JP2012521994A (ja) 2009-03-24 2012-09-20 ギリアード カリストガ エルエルシー ２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
EA201101507A1 (ru) 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
EA201270184A1 (ru) 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Лечение расстройств печени ингибиторами pi3k
WO2013105985A1 (en) * 2011-02-28 2013-07-18 Philadelphia Health & Education Corporation Small molecule inhibitors of rad51 recombinase and methods thereof
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
KR20170012560A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
JP7177937B2 (ja) 2018-12-14 2022-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 １，２－ジヒドロピリジン化合物の水性医薬製剤
IL295088A (en) 2020-01-29 2022-09-01 Kamari Pharma Ltd Compounds and preparations for use in the treatment of skin disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1994026746A1 (en) 1993-05-06 1994-11-24 Novo Nordisk A/S [1,2,4]TRIAZOLO[4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
IL130900A0 (en) 1997-02-28 2001-01-28 Pfizer Prod Inc Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts

Also Published As

Publication number Publication date
AU730503B2 (en) 2001-03-08
TNSN97087A1 (fr) 2005-03-15
EP0901487B1 (en) 2003-06-04
TW539675B (en) 2003-07-01
CN1218464A (zh) 1999-06-02
IS4881A (is) 1998-10-27
CZ352698A3 (cs) 1999-11-17
ID17149A (id) 1997-12-04
BR9709085A (pt) 1999-08-03
DE69722613D1 (de) 2003-07-10
AU1554997A (en) 1997-12-05
OA10918A (en) 2001-10-25
YU19197A (sh) 1999-09-27
NO985293L (no) 1999-01-13
CA2252907C (en) 2005-05-17
MA26430A1 (fr) 2004-12-20
NO985293D0 (no) 1998-11-13
KR20000011054A (ko) 2000-02-25
US6303615B1 (en) 2001-10-16
PT901487E (pt) 2003-08-29
JPH11514663A (ja) 1999-12-14
TR199802296T2 (xx) 1999-02-22
CA2252907A1 (en) 1997-11-20
DE69722613T2 (de) 2004-05-13
PL330042A1 (en) 1999-04-26
AP1148A (en) 2003-02-28
GT199700049A (es) 1998-10-21
ZA974156B (en) 1998-11-16
CZ295565B6 (cs) 2005-08-17
CN1103772C (zh) 2003-03-26
AP9701003A0 (en) 1997-07-31
DZ2237A1 (fr) 2002-12-03
HUP9902148A2 (hu) 2000-04-28
ES2198546T3 (es) 2004-02-01
IL126589A0 (en) 1999-08-17
SK152098A3 (en) 2000-05-16
EA199800923A1 (ru) 1999-06-24
DK0901487T3 (da) 2003-08-25
HRP970261B1 (en) 2003-06-30
SK284108B6 (sk) 2004-09-08
HRP970261A2 (en) 2000-12-31
EP0901487B9 (en) 2004-09-29
KR100375155B1 (ko) 2003-08-19
EA002905B1 (ru) 2002-10-31
HUP9902148A3 (en) 2002-11-28
JP3241388B2 (ja) 2001-12-25
WO1997043276A1 (en) 1997-11-20
CN1420114A (zh) 2003-05-28
ATE242232T1 (de) 2003-06-15
HK1019607A1 (en) 2000-02-18
HN1997000052A (es) 1997-06-26
EP0901487A1 (en) 1999-03-17
AR007118A1 (es) 1999-10-13
IL126589A (en) 2003-06-24
BG102999A (en) 1999-09-30

Similar Documents

Publication Publication Date Title
SI0901487T1 (en) 2,3,6 trisubstituted-4(3h)-quinazolinones
ZA962522B (en) Quinazoline derivatives.
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
HU9600114D0 (en) 2,8-disubstituted quinazolinones
GB9607729D0 (en) Quinazoline derivatives
ZA9710429B (en) Broad-spectrumδ-endotoxins.
GR3033254T3 (en) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
ZA978304B (en) 3-alkyl-3-phenyl-piperidines.
DE69723848D1 (en) 3-descladinose-2,3-anhydroerythromycin-derivate
HRP970260A2 (en) 2,4-diaminopyrimidine derivatives
ZA95269B (en) Quinazoline-2,4-diones
ZA97928B (en) Novel heteroaryl-oxazolidinones.
ZA974052B (en) New benzothiazolinones.
HU9700609D0 (en) 1,25-dihydroxy-12,22,23-trisdehydro-cholecalciferol derivatives
ZA974056B (en) New thiazolopyridines.
ZA981529B (en) Substituted 2,4-diaminopyrimidine
AU1160P (en) NO. 001 Juniperus conferta
PL332044A1 (en) 25-methylene and 24,25-epoxy marcphortines and paraherquamides
GB9700695D0 (en) Quinazoline derivatives
GB9603049D0 (en) Quinazoline derivatives
GB9606865D0 (en) Quinazoline derivatives
ZA965384B (en) 4-Amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives
ZA977581B (en) Novel aryl-pyridazines.